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Abstract
Background: In low- and middle-income countries (LMICs), the burden of non-communicable diseases (NCDs) is
growing against an existing burden of other diseases such as HIV/AIDS. Integrated models of care can help address
the rising burden of multi-morbidity. Although integration of care can occur at various levels and has been defined
in numerous ways, our aim is to assess the effects of integration of service delivery at primary healthcare level in LMICs.
Methods: We will consider randomised controlled trials (RCTs), cluster RCTs, non-randomised trials, controlled before-
after studies and interrupted time series that examine integrated models of care among people with multi-morbidities,
of which diabetes or hypertension is one, living in LMICs. We will compare fully integrated models of care to stand-
alone care, partially integrated models of care to stand-alone care and fully integrated models to partially integrated
models of care. Primary outcomes include all-cause mortality, disease-specific morbidity, HbA1c, systolic blood pressure
and cholesterol levels. Secondary outcomes include access to care, retention in care, adherence, continuity of care,
quality of care and cost of care. We will conduct a comprehensive search in the following databases: MEDLINE,
EMBASE, the Cochrane Central Register of Control Trials, LILACS, Africa-Wide Information, CINAHL and Web of Science.
In addition, we will search trial registries, relevant conference abstracts and check references lists of included studies.
Selection of studies, data extraction and assessment of risk of bias will be performed independently by two review
authors. We will resolve discrepancies through discussion with a third author. We will contact study authors in case of
missing data. If included studies are sufficiently homogenous, we will pool results in a meta-analysis. Clinical
heterogeneity related to the population, intervention, outcomes and context will be documented in table
format and explored through subgroup analysis. We will assess χ2and I2 tests for statistical heterogeneity. We will use
GRADE to make judgements about the certainty of evidence and present findings in a summary of findings table.
Discussion: In light of limited evidence on the provision of comprehensive care for diabetes and hypertension, and its
comorbidity in LMCIs, we believe that the findings of this systematic review will provide a synthesis of evidence on
effective models of integrated care for diabetes and hypertension and their comorbidities at primary healthcare level.
This will enable policy-makers to device policies and programs that are evidence informed.
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Background
The burden of non-communicable disease (NCDs) in low-
and middle-income countries (LMICs) exceeds that of
high-income countries [1]. In 2015, a total of 40 million
people in LMICs died of NCDs (80% of deaths) of which
15 million deaths were premature and occurred between
the ages of 30–70 years, the prime productive age of em-
ployment in most LMICs [1, 2]. This implies that NCDs
are a threat to the health of adults in LMICs, to workplace
productivity and to the health of economies [3].
NCDs are an umbrella term referring to cardiovascular
diseases (heart attacks and stroke), cancers, chronic re-
spiratory diseases (such as chronic obstructive pulmonary
disease and asthma) and diabetes. Most NCD deaths are
caused by cardiovascular diseases (17.7 million deaths per
year) followed by cancers (8.8 million deaths per year), re-
spiratory diseases (3.9 million deaths per year) and dia-
betes (1.6 million deaths per year) [1]. NCDs account for
the majority of illness in all regions of the world other
than sub-Saharan Africa.
Although exposure to risk factors is the main cause of
premature NCD deaths, an inadequate response to the
healthcare needs of affected patients contributes a great
deal [4]. Diabetes and hypertension are the major cardio-
vascular risks leading to target organs’ damage such as the
brain, heart and kidney. Currently, the number of people
with diabetes is estimated to be 425 million and it is ex-
pected to increase up to 629 million in 2045, and its burden
is reported to be serious in productive age [5]. Similarly, the
prevalence of hypertension is increasing worldwide particu-
larly in LMICs. According to the International Society of
hypertension (ISH), around 40% of people over age of
25 years have hypertension worldwide and two third of
them live in LMICs [6]. In addition to standalone burden,
hypertension and diabetes co-morbidity have been reported
to have a synergistic impact on bad cardiovascular disease
outcomes [7].
Multi-morbidities of NCDs
Multi-morbidity is defined as the presence of two or
more chronic medical conditions in an individual [8].
Multi-morbidity of NCDs poses a global healthcare chal-
lenge. In most LMICs, co-morbidity of NCDs and com-
municable diseases (CDs) is increasing [9, 10]. The
interaction between NCDs and CDs, particularly with
human immunodeficiency virus (HIV) and its treatment
with cardio-metabolic disorders, and between smoking,
diabetes and tuberculosis (TB) has been highlighted in
the literature [10, 11].
Due to improved treatment programs for HIV, people
living with HIV (PLWH) are living longer with an in-
creasing risk of developing NCDs due to direct nature of
HIV infection, shared risk factors and treatment side ef-
fects of HIV [10–12].
Antiretroviral treatment (ART) of HIV infection in-
creases the risk of hyperlipidaemia and diabetes. In
addition, PLWH have a high risk of contracting NCDs
through the risk associated with increasing age [9, 13].
Moreover in LMICs, HIV remains a major threat
among vulnerable groups and particularly in some parts
of Africa where HIV and AIDS are the greatest cause of
life-years lost [14, 15].
Beside the epidemiological link between NCDs and
CDs, studies in the literature highlight interaction be-
tween NCDs and psychological disorders such as depres-
sion [16, 17].
A study conducted in Nigeria shows that the preva-
lence of depression was 28% in diabetic patients and
27% in patients with hypertension [18]. In light of
multi-morbidity of NCDs in particular diabetes and car-
diovascular diseases, it is imperative for LMICs to have a
strong and dynamic health system that can respond ef-
fectively to the growing burden of multi-morbidity.
Management of NCDs
In 2010, the WHO published a Package of Essential
NCDs (PEN) interventions for primary healthcare
(WHO PEN) to assist low-income countries for early de-
tection and management of NCDs at primary healthcare
(PHC) level [19]. WHO PEN, provides a package of set
cost-effective interventions to be delivered at low cost
and acceptable quality of care, but it does not indicate
how these interventions can be delivered in an inte-
grated manner with other chronic diseases such as HIV
[19]. Hence, NCDs such as diabetes and hypertension
are still managed separately from other chronic diseases
such as TB and HIV [20].
In order to curtail the burden of NCDs and its
co-morbidities, LMICs should consider accelerating the
provision of comprehensive care and integrated strat-
egies to improve health service delivery, efficiency and
equity [13].
A paradigm shift from vertical programs towards inte-
grated approach is required to address shared NCDs
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risks and socio-economic determinant factors [9, 21].
Haldane and colleagues argue that integrated models of
care provide people with holistic options centred on
health needs of people and communities and thereby en-
hance community self-reliance [21].
Need for integrated approach for management of NCDs
Given the multiple comorbidities of hypertension and
diabetes, they require comprehensive care that is
health-centred rather than disease-tailored, particularly
in LMICs where both the burden of NCDs and CDs is
rising [13]. In addition, LMICs need health systems that
can respond more effectively and equitably to the health-
care needs of people with NCDs in order to reduce mor-
bidity, disability and death from NCDs, and contribute
to better overall health outcomes [4].
The term integration is mostly defined in the literature
as “managerial or operational changes to health systems to
bring together inputs, delivery, management and
organization of particular service functions as means of
improving coverage, access, quality, acceptability and
cost-effectiveness” [22]. This may include service integra-
tions that combine “different packages of services such as
integration of service delivery points, integration at differ-
ent levels of service delivery, process modifications, intro-
duction of technologies aimed at aiding integration, and
integration of management decisions” [23, 24].
Lately, most policy-makers and researchers advocate for
integrated approach or programs because integrated pro-
grams increase system effectiveness and cost-effectiveness,
particularly in low-resource settings [13, 25, 26].
Curry and Ham (2012) as well as Valentijn and col-
leagues (2013) propose typologies of integrated care. This
typology differentiates integration at micro-level as pa-
tient focused, such as case management, whereas
meso-level integration focuses on groups of patients or
population, and macro-level integration focuses on health
systems [23, 24]. Within these levels, the typology distin-
guishes integration types.
We classify clinical integration as care integrated into
a single process through shared guidelines and protocols
across professions, and service integration as different
clinical services integrated within an organisation and
provided through single healthcare worker or multidis-
ciplinary teams.
In recent years, guidelines, as well as research from
LMICs (and sub-Saharan Africa in particular), have fo-
cused on integration of HIV/AIDS and TB services at
service delivery level of the health system [15, 27, 28].
Drawing on these and other models of care, we have
conceptualised integrated care as partial integration and
full integration of service delivery as illustrated in a logic
model of integrated care for diabetes and hypertension
(Fig. 1). In this model, we assume that a patient has
already entered the health system (i.e. through a PHC
clinic and or community level) either for treatment of
diabetes or hypertension, or for treatment of any other
chronic disease such as HIV.
In a fully integrated model of service delivery, a patient
with more than one chronic disease should receive the
full package of care for all diseases at a single point of
care. This “one-stop-shop” model refers to horizontal in-
tegration of primary healthcare and community health
services and can involve one or more healthcare profes-
sionals. In a partially integrated model of service deliv-
ery, patients receiving treatment for one disease receive
additional care related to prevention, diagnosis or treat-
ment of another disease, but do not receive the full
package of care (Fig. 1).
Rationale for systematic review
We conducted a scoping review (date of last search 8 No-
vember 2016) to assess existing evidence on the effective-
ness of integrated models of care in people with diabetes
or hypertension and any other comorbid disease [29]. We
identified five systematic reviews, of which two examined
collaborative care for diabetes and depression, two looked
at collaborative care for various diseases including dia-
betes and depression, hypertension and diabetes, and
hypertension and depression; and one focused on task-
shifting and management of cardiovascular diseases and
diabetes [29]. However, none of the included reviews ex-
amined collaborative care for diabetes or hypertension
and communicable diseases, and only one review that
assessed task-shifting included studies from LMICs.
Subsequently, another review by Haldane et al. [21]
examined existing programmes that integrated health-
care delivery for diabetes, hypertension or CVDs with
HIV/AIDS (date of last search October 2015). They in-
cluded 17 studies of which most described existing pro-
grammes and eleven of these described programmes
were in sub-Saharan Africa. Although this is useful for
planning and development, there is a lack of data on the
effectiveness of these programmes.
In addition, little was found on factors that facilitate or
hinder integration of hypertension and diabetes with
co-morbidities in LMICs. Another descriptive study from
Cambodia on the management of HIV/AIDS, diabetes and
hypertension showed that integration of these services was
highly acceptable and led to good health outcomes [30].
A Cochrane review by Dudley and Garner assessed the
effectiveness of strategies to integrate primary healthcare
services in LMICs [31]. They included studies that inte-
grated family planning into existing services; nutrition and
infectious disease interventions; and sexually transmitted
infections, HIV/AIDS and TB treatment. None of the in-
cluded studies reported on services linked to NCDs.
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There is thus little up-to-date evidence from LMICs
on the effectiveness of integrated healthcare delivery for
people with NCDs, and diabetes and hypertension in
particular. With a rising burden of diabetes and hyper-
tension, in combination with the existing high burden of
infectious diseases and resource constrained health sys-
tems in LMICs, there is a need to optimise healthcare
delivery to benefit both the patients and the health
systems.
The objective of this systematic review is to assess the
effects of integrated models of care at PHC level for
people living in LMICs, with multi-morbidity, of which
diabetes or hypertension is one, compared to no inte-
grated care on health and process outcomes.
Methods
This protocol is reported according to the PRISMA-P
checklist [32] (Additional file 1).
Criteria for considering studies for the review
 Types of participants
We will include studies examining people with
multi-morbidity, of which diabetes and/or hypertension
is one, living in LMICs, irrespective of age. We define
multi-morbidity as the presence of two or more chronic
medical conditions in an individual [8]. Studies address-
ing both adults and children will be considered. LMICs
will be defined according to the classification of the
World Bank [33].
 Types of interventions
This review will only consider studies that describe in-
tegration of service delivery at PHC and community
level. We will consider models of partial integration and
full integration of service delivery (Fig. 1). Partial inte-
gration of service delivery will be defined as models
where patients treated for diabetes, hypertension or any
other chronic disease receive part of the package of care
(prevention, diagnosis, treatment) for another disease.
Full integration of service delivery will be defined as
models where patients (primarily treated for diabetes,
hypertension or any other disease) receive the full
Fig. 1 Logic model of models of integrated care for diabetes and hypertension
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package of care (prevention, diagnosis and treatment)
for diabetes/hypertension and any other chronic disease
at the same point of care by one or more healthcare
professionals.
 Types of comparisons
The main comparison will be stand-alone models of
care, defined as models of care that are limited to one
disease. We will include the following comparisons:
◦ Fully integrated models of care vs. stand-alone care
◦ Partially integrated models of care vs. stand-alone care
◦ Fully integrated models of care vs. partially integrated
models of care
 Types of outcomes
We will include studies that report on either primary
health outcomes or secondary outcomes. However, the
absence of reporting the pre-specified health and process
outcomes will not be a deciding factor for inclusion of
studies. Types of outcomes to consider are the following:
Primary outcomes (health outcomes)
▪ All-cause mortality
▪ Disease specific morbidity as reported in included
studies (e.g. disease control metrics, quality of life)
▪ Glycated haemoglobin (HbA1c)
▪ Systolic blood pressure (BP)
▪ Cholesterol levels
Secondary outcomes (process outcomes)
▪ Access to care as reported in the included studies
▪ Retention in care and adherence as reported in the
included studies
▪ Continuity of care as reported in the included studies
▪ Quality of care as reported in the included studies
▪ Cost of care as reported in the included studies
 Types of studies
We will consider randomised controlled trials (RCTs),
including cluster RCTs, controlled (non-randomised) clin-
ical trials (CCTs) or cluster trials, interrupted time series
(ITS) studies with at least three data points before and
after the intervention, and controlled before-and-after
(CBA) studies for inclusion. Cluster randomised, cluster
non-randomised or CBA studies will be included only if
there are at least two intervention sites and two control
sites. Cross-sectional studies, case series and case reports
will be excluded.
Search methods for identifying studies
We will search the following electronic databases: MED-
LINE (PubMed), EMBASE (Ovid), the Cochrane Central
Register of Control Trials (CENTRAL), LILACS, Africa-
Wide Information (via EBSCO host), CINAHL, Web of
Science (Core collection). For ongoing studies, we will
search the following trial registries: WHO ICTRP and
Clinicaltrials.gov. We will search conference abstracts
from the International AIDS Society Online Resource Li-
brary, the HIV/AIDS Implementers’ Meetings and the
NCDs Alliance meetings.
Search terms will include ‘diabetes’, ‘hypertension’, ‘co-
morbidities , ‘integrated healthcare delivery’, ‘low- and
middle-income countries’ and their synonyms. The full
search strategy for MEDLINE (PubMed) is provided in
Additional file 2. We will adapt it for other electronic
databases. We will report all search strategies in full in the
final version of the review. In addition, we will screen ref-
erence lists of included studies and reference lists of rele-
vant systematic reviews, and contact experts in the field
and relevant organisations (e.g. NCD Alliance) for unpub-
lished studies. All languages will be included.
Study selection and data extraction
 Selection of studies
Two authors will independently screen titles and ab-
stracts of studies identified by the search using Covidence
software, and we will retrieve full-text of all potentially eli-
gible studies. Two authors will independently screen full
texts for eligibility. Discrepancies in the selection process
will be resolved through discussion or by consulting a third
author. Studies will be classified as included, excluded or
awaiting assessment. We will provide reasons for excluding
studies. Studies only available as abstracts will be included
in the general results of the review, but not in the analysis.
 Data extraction
We will extract data based on the description of various
models of integrated care as illustrated in Fig. 1 with con-
sideration of possible scenarios of various packages of care
provided in terms of partial integration. A pre-specified,
standardised and piloted data extraction form will be used.
Two authors will independently extract data and compare
the results. Discrepancies will be resolved by discussion or
by consulting a third reviewer. We will contact study au-
thors in case of missing data. We will extract data on the
participants, intervention, comparisons, outcomes, setting,
context and funding sources.
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Data items will be in line with recommendations from
the template for intervention description and replication
(TIDieR) [34] and the PRISMA-Complex Interventions
(CI) extension checklist [35]. We will look at the follow-
ing items:
▪ Provide name or a phrase to describe the intervention
▪ Rationale, theory or goal of the element essential to
the intervention
▪ Materials used
▪ Procedures or processes used in the intervention
▪ Who provided—each category of the intervention
provider
▪ Describe modes of delivery of the intervention
▪ Types of location where the intervention took place
▪ When and how much—number of times the
intervention was delivered
▪ Tailoring of the intervention
▪ How well the intervention was planned
▪ Replicability
For the ‘implementation components’, we will look at
the following items:
▪ Clearly define the adoption, uptake or integration
strategies
Integration strategies may include facilitators (distinct
from intervention elements) such as attestations, financial
incentives, periodic reports of findings, reminders, supple-
mental trainings or physical environmental changes.
Where there is insufficient detail reported in the study,
we will contact the study investigators for clarity or
more information on the study. Disagreements will be
resolved first by discussion and then by consulting at
third author for consensus.
 Risk of bias assessment
For randomised controlled trials, non-randomised tri-
als and controlled before-after studies, we will use the
tool proposed by the Effective Practice and Organisation
of Care (EPOC) group [36]. We will assess the following
nine domains as having ‘low risk’, ‘high risk’ or ‘unclear
risk’ of bias: (1) random sequence generation, (2) alloca-
tion concealment, (3) baseline outcome measurements,
(4) baseline characteristics, (5) incomplete outcome data,
(6) knowledge of allocated intervention (blinding), (7)
protection against contamination, (8) selective outcome
reporting and (9) other risks of bias. For cluster RCTs,
we will assess additional risk of bias linked to recruit-
ment, baseline differences, loss of clusters, incorrect ana-
lysis and compatibility with RCTs randomised by
individuals. For ITS studies, we will also use the tool
proposed by EPOC to assess whether: (1) the interven-
tion was independent of other changes, (2) the shape of
the intervention effect was pre-specified, (3) the inter-
vention was unlikely to affect data collections, (4) know-
ledge of the allocated intervention was adequately
prevented during the study, (5) incomplete outcome data
was likely to bias results, (6) outcomes were reported se-
lectively and (7) there were any other risks of bias. For
each domain, risk of bias will be assessed as low, high or
unclear. Two authors will independently assess risk of
bias of included studies. We will resolve discrepancies
through discussion or consulting a third author.
Data analysis
 Measures of treatment effect
We will extract relevant outcome data for each study
and enter it into Review Manager 5. For dichotomous out-
comes, we will calculate risk ratios (RR) and report pooled
effects with 95% confidence intervals. For continuous out-
comes, we will calculate the mean differences (MD) if out-
comes were measured in the same way across studies or
standardised mean differences (SMD) where outcomes
were measured differently across studies. We will report
pooled effects with 95% confidence intervals.
 Unit of analysis issues
Where cluster RCTs have appropriately adjusted for the
effects of clustering in their analysis, we will use these ad-
justed effect estimates and standard errors in our
meta-analysis using the generic inverse-variance method
in Review Manager 5 [37]. Where the included cluster
RCTs did not perform any adjustment for clustering, we
will adjust the raw data ourselves using the intra-class cor-
relation coefficient (ICC). If the study authors do not re-
port an ICC value in the published article, either we will
obtain this value from similar studies or we will estimate
the ICC value. We will not present results from cluster
RCTs that were not adjusted for clustering. If we estimate
the ICC value, we will perform sensitivity analyses to in-
vestigate the robustness of our analyses. Where multi-arm
studies (e.g. two intervention arms and one control arm)
contribute multiple comparisons to a specific analysis, we
will split the ‘shared group’ to avoid including data from
the same participant more than once.
 Dealing with missing data
We will contact the study authors to request missing
data if needed. If after contacting the authors, there are
still missing data and we consider the data to be missing
at random, we will include only the data available in the
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analysis. Otherwise, we will impute the missing data and
account for the data imputed with uncertainty in line
with the Cochrane Handbook of Systematic Reviews of
Interventions [38]. We will then conduct a sensitivity
analysis to analyse how sensitive the results are to the
assumptions we made when imputing missing data and
analyse all data as intention-to-treat.
 Assessment of heterogeneity
We will explore clinical heterogeneity by clearly docu-
menting study characteristics related to the population,
intervention, outcomes and context in table format. We
will assess the statistical heterogeneity in each
meta-analysis by inspecting forest plots and calculating χ2
test values and I2 statistics. We will consider significant
heterogeneity present if the P value of the χ2 test is < 0.10.
We will interpret the I2 statistic according to the thresh-
olds recommended in the Cochrane Handbook of System-
atic Reviews of Interventions [39]. Therefore, we will
consider an I2 value above 30% to indicate important het-
erogeneity. In addition, we will explore the causes of stat-
istical heterogeneity by conducting subgroup analyses.
 Assessment of reporting biases
We will examine reporting biases by means of funnel
plots, if we are able to pool more than 10 studies per
outcome in a meta-analysis.
 Data synthesis
We will organise the review findings according to the
proposed models of integrated care as depicted in Fig. 1.
We will pool data from individual studies if they are suf-
ficiently homogeneous in terms of design, population,
intervention and comparator. As we anticipate some de-
gree of heterogeneity, we will perform random-effects
meta-analysis. We will not pool data from RCTs and
non-randomised studies in a single meta-analysis. If we
judge included studies to be too heterogeneous to pool,
we will make use of narrative synthesis and present data
in table format.
 Subgroup analysis
We will carry out the following subgroup analyses on
primary outcomes to explore heterogeneity: various
co-morbidities (e.g. patients with diabetes and HIV vs pa-
tients with diabetes and depression), clinic vs. community
level and age category (children, age 1–10 years vs. adoles-
cents, age 10 to 19 years vs. adults, age > 19 years).
 Sensitivity analysis
We will carry out the following sensitivity analyses on
primary outcomes:
– To examine the effect of excluding studies of high
risk of bias
– To examine the effect of various ICCs in case of
adjusting outcomes for clustering ourselves
– To examine the effect of imputed data
 Summary of findings table and certainty of evidence
We will assess the certainty of the evidence for primary
outcomes (all-cause mortality, disease-specific morbidity,
HbA1c, BP, cholesterol levels) using GRADE. We will cre-
ate a ‘summary of findings’ table using GRADEpro soft-
ware [40]. In the table, we will display the model of
integrated care, primary outcomes (e.g. all-cause mortality,
disease-specific morbidity) of the review, the comparative
risks between intervention and control groups, the relative
effects with 95% CI, the number of participants in the
studies and the certainty of evidence.
The five domains that we will consider for our judge-
ment to downgrade the certainty of evidence comprise
study limitations, inconsistency, imprecision, indirect-
ness and publication bias. We will consider upgrading
the certainty of evidence if there is a large effect, a
dose-response and cases where all plausible residual
confounding would reduce a demonstrated effect or
would suggest a spurious effect if no effect was ob-
served. The quality of evidence for each outcome will be
described as high, moderate, low or very low [41].
Discussion
Given the rising burden of NCDs in light of communic-
able diseases in LMICs, policy-makers and healthcare pro-
fessionals are seeking ways to provide comprehensive care
to people with multi-morbidity. However, there is a lack
of evidence on the effectiveness of integrated models of
care in LMICs, hindering implementation of such models.
Our systematic review aims to address this gap in evi-
dence by providing an up-to-date and comprehensive syn-
thesis of existing research. We will ensure methodological
rigour by conducting an extensive search, systematically
screening and selecting studies, extracting data and asses-
sing the risk of bias of included studies. Furthermore, we
will use GRADE to assess the quality of evidence. We have
been engaging with policy-makers from the onset of this
protocol, have involved them in the process of defining
and clarifying the review question. We are also planning
to continue this engagement throughout the review
process. Hence, we believe that the findings of this sys-
tematic review will be relevant to policy-makers and in-
form policy and practice in LMICs.
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